Enhanced overall survival (27.0 months) and progression-free survival (8.0 months) were observed in the HAIC-len-p group compared to the len-p alone group (9.0 months and 3.0 months, respectively, p <0.001). The objective response rate was significantly higher in the HAIC-len-p cohort (67.3% vs. 29.1%, p <0.001). Notably, the combination therapy did not lead to a higher incidence of severe adverse events compared to len-p alone, indicating its potential as a safer alternative treatment.
• Why it matters: There are limited treatment options for advanced HCC.
Multicenter Study by Guan R, Zhang N (…) Guo R et 9 al. in Int J Surg
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.